<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535271</url>
  </required_header>
  <id_info>
    <org_study_id>SOC-2101</org_study_id>
    <nct_id>NCT04535271</nct_id>
  </id_info>
  <brief_title>Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma</brief_title>
  <acronym>TAGGED</acronym>
  <official_title>TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Leiomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarcoma Oncology Research Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarcoma Oncology Research Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and&#xD;
      dacarbazine given intravenously.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and&#xD;
      dacarbazine given intravenously.&#xD;
&#xD;
      A total of 80 patients will receive trabectedin 0.5 mg/m2 as 24 hour continuous intravenous&#xD;
      infusion (CIV) on D1 and D8, gemcitabine 250 mg/m2 i.v. on D1 and D8, and dacarbazine 250&#xD;
      mg/m2 i.v. on D1 and D8 (see product information; www.accessdata.fda.gov). Treatment cycles&#xD;
      are given every 3 weeks. Patients in this study may continue treatment until significant&#xD;
      disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who&#xD;
      withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will&#xD;
      be replaced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Progression free survival up to disease progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Best overall response (BOR) and duration of response (DOR) by RECIST v1.1 via CT scan or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of treatment-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Dacarbazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female ≥ 18 years of age&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic&#xD;
             leiomyosarcoma&#xD;
&#xD;
          -  Previously treated patient with measurable disease by RECIST v1.1&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Acceptable liver function: Bilirubin &lt; 1.5 times upper limit of normal (ULN; except&#xD;
             subjects with Gilbert Syndrome who must have a total bilirubin level &lt; 3.0 ULN); AST&#xD;
             (SGOT), ALT (SGPT) and alk phos &lt; 2.5 x ULN (&lt; 5 x ULN if liver metastases present)&#xD;
&#xD;
          -  Acceptable renal function: Creatinine &lt; 1.5 times ULN and creatinine clearance &gt; 60&#xD;
             ml/min using the Crockroft-Gault formula&#xD;
&#xD;
          -  Acceptable hematologic status: ANC &gt;1000 cells/μL; Platelet count &gt;100,000/μL;&#xD;
             Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  INR and PT &lt; 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT&#xD;
             must be within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          -  Ability to understand the purposes and risks of the study and has signed and dated a&#xD;
             written informed consent form approved by the Investigator's IRB/Ethics Committee&#xD;
&#xD;
          -  Willingness to comply with all study procedures and availability for the duration of&#xD;
             the study&#xD;
&#xD;
          -  All women of childbearing potential must have a negative urine or serum pregnancy test&#xD;
             within 72 hours of enrollment. If urine test is positive or cannot be confirmed as&#xD;
             negative, a serum pregnancy test will be required; all subjects must agree to use&#xD;
             highly effective means of contraception (surgical sterilization or the use of barrier&#xD;
             contraception with either a condom or diaphragm in conjunction with spermicidal gel or&#xD;
             an IUD) with their partner from entry into the study through 5 months for women and 7&#xD;
             months for men after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving treatment with another investigational device or drug study, or&#xD;
             &lt;14 days since ending treatment with another investigational device or drug study(s).&#xD;
&#xD;
          -  Subject has known sensitivity to trabectedin, gemcitabine or dacarbazine.&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding or planning to become pregnant during&#xD;
             study treatment and through 3 months after the last dose of trabectedin, gemcitabine&#xD;
             or dacarbazine.&#xD;
&#xD;
          -  Female subject of childbearing potential who is unwilling to use acceptable method(s)&#xD;
             of effective contraception during study treatment and through 3 months after the last&#xD;
             dose of trabectedin, gemcitabine or dacarbazine.&#xD;
&#xD;
          -  Sexually active subjects and their partners unwilling to use male or female latex&#xD;
             condom&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sant P Chawla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarcoma Oncology Research Center, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sant P Chawla, MD</last_name>
    <phone>3105529999</phone>
    <email>santchawla@sarcomaoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Chua-Alcala, MD</last_name>
    <phone>3105529999</phone>
    <email>vchua@sarcomaoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sant P Chawla</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sant P Chawla, MD</last_name>
      <phone>310-552-9999</phone>
      <email>santchawla@sarcomaoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Chua-Alcala, MD</last_name>
      <phone>3105529999</phone>
      <email>vchua@sarcomaoncology.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014 Jul;5(3):186-92. doi: 10.4103/0976-500X.136098. Review.</citation>
    <PMID>25210398</PMID>
  </reference>
  <reference>
    <citation>www.accessdata.fda.gov/drugsatfda_docs (Trabectedin, Gemcitabine, Dacarbazine)</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

